SP
BravenNow
Stokes Frank sells Castle Biosciences (CSTL) stock worth $192k
| USA | economy | ✓ Verified - investing.com

Stokes Frank sells Castle Biosciences (CSTL) stock worth $192k

#Stokes Frank #Castle Biosciences #Insider Trading #CSTL stock #Financial Results #NASDAQ #Stock Sales

📌 Key Takeaways

  • CFO Frank Stokes sold 7,000 shares of Castle Biosciences stock worth approximately $192,000
  • The stock has declined 5.6% in the past week but remains up 35.6% over the past year
  • Despite recent weakness, the stock trades below its Fair Value according to InvestingPro
  • Castle Biosciences reported strong Q4 2025 financial results, surpassing both earnings and revenue expectations

📖 Full Retelling

Castle Biosciences Chief Financial Officer Frank Stokes sold 7,000 shares of company stock worth approximately $192,000 on March 3, 2026, in the midst of recent market volatility affecting the NASDAQ-listed biotech firm. The transactions were executed at prices ranging from $27.32 to $27.81, with the first sale involving 5,300 shares at a weighted average price of $27.32 and the second consisting of 1,700 shares at a weighted average price of $27.81. This insider sale occurred as the stock experienced a 5.6% decline over the past week, though shares remain up 35.6% over the past year. Beyond these sales, Stokes also disposed of 14,343 additional shares on March 3-4 to cover tax obligations while simultaneously acquiring 27,946 shares through option exercises and receiving 48,367 Restricted Stock Units on March 4. Despite recent weakness, InvestingPro analysis suggests the stock trades below its Fair Value, positioning it among undervalued opportunities. The company's recent financial performance provides context for these transactions, as Castle Biosciences reported fourth-quarter 2025 results that significantly exceeded expectations, with a diluted loss per share of $0.08 compared to the forecasted $0.32, and revenue of $87 million surpassing the anticipated $77.09 million by 12.86%. Following these results, Canaccord Genuity maintained a Buy rating on the stock with a $50 price target, citing performance that exceeded both the firm's expectations and FactSet consensus.

🏷️ Themes

Insider Trading, Stock Market Performance, Corporate Financials

📚 Related People & Topics

Insider trading

Insider trading

Trading using nonpublic information

# Insider Trading **Insider trading** is the trading of a public company's stock or other securities (such as bonds or stock options) based on **material, nonpublic information** about the company. While the practice is common, its legality is subject to complex regulations that vary significantly ...

View Profile → Wikipedia ↗

Entity Intersection Graph

Connections for Insider trading:

🌐 SEC filing 17 shared
🌐 Restricted stock 4 shared
👤 New York Stock Exchange 3 shared
🌐 EVP 3 shared
🌐 Vice president 3 shared
View full profile

Mentioned Entities

Insider trading

Insider trading

Trading using nonpublic information

Deep Analysis

Why It Matters

The sale of Castle Biosciences (CSTL) stock by its CFO Frank Stokes at a time of recent volatility raises potential concerns about insider trading implications and internal sentiment regarding the company’s future performance. Simultaneously, the company’s strong financial results—exceeding analyst expectations—could signal broader confidence despite short-term market fluctuations." "context_background": [ "Frank Stokes’ sale of $192k worth of CSTL stock coincides with a 5.6% weekly decline but contrasts with a 35.6% year-over-year gain, suggesting mixed internal and external perceptions.", "The company’s recent fourth-quarter results (Q4 2025) showed surprising profitability: $87M revenue (12.86% beat), diluted loss per share of -$0.08 (vs. forecasted -$0.32), reinforcing its undervaluation despite short-term market pressures.", "Canaccord Genuity’s ‘Buy’ rating and $50 price target reflect optimism, while insider activity—including tax-related disposals and option exercises—may indicate hedging or strategic rebalancing.", "Timing of the sale (March 3–4) aligns with broader market trends like geopolitical tensions (Iran conflict) and regulatory discussions on AI exports, which could impact tech sector sentiment." ], "what_happens_next": "If insider activity remains stable, further positive financial performance could sustain investor confidence despite recent stock dips. However, if the CFO’s sale signals broader concerns about valuation or operational risks, it may trigger additional scrutiny from regulators and analysts. The company’s strong Q4 results could also attract more institutional investment, reinforcing its undervaluation perception." "faq": [ { "question": "What does Frank Stokes’ insider stock sale imply?

Context & Background

  • Frank Stokes’ sale of $192k worth of CSTL stock coincides with a 5.6% weekly decline but contrasts with a 35.6% year-over-year gain, suggesting mixed internal and external perceptions.
  • The company’s recent fourth-quarter results (Q4 2025) showed surprising profitability: $87M revenue (12.86% beat), diluted loss per share of -$0.08 (vs. forecasted -$0.32), reinforcing its undervaluation despite short-term market pressures.
  • Canaccord Genuity’s ‘Buy’ rating and $50 price target reflect optimism, while insider activity—including tax-related disposals and option exercises—may indicate hedging or strategic rebalancing.
  • Timing of the sale (March 3–4) aligns with broader market trends like geopolitical tensions (Iran conflict) and regulatory discussions on AI exports, which could impact tech sector sentiment.

What Happens Next

If insider activity remains stable, further positive financial performance could sustain investor confidence despite recent stock dips. However, if the CFO’s sale signals broader concerns about valuation or operational risks, it may trigger additional scrutiny from regulators and analysts. The company’s strong Q4 results could also attract more institutional investment, reinforcing its undervaluation perception." "faq": [ { "question": "What does Frank Stokes’ insider stock sale imply?

}
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil extends weekly gains as Iran conflict rages on, with crude surging around 18% Trump replaces Homeland Security chief Kristi Noem Wall Street ends lower on escalating Iran conflict, report of AI export curbs Trump says he must be involved in selecting Iran’s next leader (South Africa Philippines Nigeria) Stokes Frank sells Castle Biosciences stock worth $192k By Insider Trading Published 03/05/2026, 07:23 PM Stokes Frank sells Castle Biosciences stock worth $192k 0 CSTL -0.92% Castle Biosciences Inc (NASDAQ:CSTL) Chief Financial Officer Frank Stokes sold 7,000 shares of common stock on March 3, 2026, in two separate transactions. The sales were executed at prices ranging from $27.32 to $27.81, netting Stokes approximately $192,073. The timing coincides with recent volatility, as the stock has declined 5.6% over the past week, according to InvestingPro data, though shares remain up 35.6% over the past year. The first sale involved 5,300 shares sold at a weighted average price of $27.32, with prices ranging from $26.70 to $27.67. The second sale consisted of 1,700 shares at a weighted average price of $27.81, with prices ranging from $27.72 to $27.97. On March 3 and 4, Stokes also disposed of 14,343 shares of common stock valued at $401,875 to cover tax obligations. Additionally, on March 4, Stokes acquired 27,946 shares of Castle Biosciences common stock through option exercises, and received 48,367 Restricted Stock Units. Despite recent weakness, InvestingPro analysis suggests the stock trades below its Fair Value, placing it among undervalued opportunities . For deeper insights, investors can access the comprehensive Pro Research Report, available for CSTL and 1,400+ US equities. In other recent news, Castle Biosciences reported its fourth-quarter 2025 financial results, surpassing both earnings and revenue expectations. The company posted a diluted loss per share of $0.08, which was significantly better ...
Read full article at source

Source

investing.com

More from USA

News from Other Countries

🇬🇧 United Kingdom

🇺🇦 Ukraine